Cargando…
2114. Evaluation of Isavuconazole Activity against Non-fumigatus Aspergillus and cryptic Aspergillus species Causing Invasive Infections Worldwide
BACKGROUND: Isavuconazole (ISC) is considered first-line therapy for the treatment of invasive aspergillosis (IA). There is limited data on antifungal susceptibility testing of clinically relevant non-fumigatus (non-AFM) and cryptic species of Aspergillus (cryAsp) causing IA. The activity of ISC and...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676911/ http://dx.doi.org/10.1093/ofid/ofad500.1737 |